The goal of this clinical trial is to evaluate the safety and effectiveness of different doses and dose intervals of Elranatamab in people with relapsed/refractory multiple myeloma.
This trial is currently open and accepting patients.
This Phase 1 / 2 clinical trial is being conducted in two different parts. It is open-label, which means that both patient and researchers will know which group they are participating in and which doses they will receive. Patients enrolling in this trial will be allowed to continue to receive Elranatamab as long as their myeloma doesn’t get worse, and they don’t develop bad side effects.
Part 1 of this study is organized into 28 day cycles. Researchers are seeking approximately 30 participants in this part of the study. All participants will be required to be hospitalized for a minimum of three days while receiving their first doses of Elranatamab in cycle 1. Patients participating in Part 1 of this study will receive Elranatamab weekly during their first 6 cycles, and every other week from cycle 7 onward if they respond well to Elranatamab.
Part 2 is the dose exploration and expansion part of this trial, and also organized into 28 day cycles. Researchers are seeking approximately 46 participants in Part 2, in up to three different groups. All participants will be required to be hospitalized for a minimum of three days while receiving their first doses of Elranatamab in cycle 1. Some patients in part 2 will also be required to be hospitalized for one day while receiving the first dose in cycle 2.
Patients in part 2 will receive one of two planned dose levels of Elranatamab weekly or every other week depending on when they join the study. After 4 and 7 cycles, some patients' dosing schedules may change to receive Elranatamab every other week and once a month respectively if they respond well to Elranatamab.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 76 patients (estimated)View More
View all clinical trial locations sorted by state.
Fort Collins, CO
Ann Arbor, MI
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.(888) 828-2206
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
SparkCures is working closely with Pfizer to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors